SEOUL PHARMA CO.,LTD.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
SEOUL PHARMA CO.,LTD. - overview
Established
1985
Location
Seoul, -, South Korea
Primary Industry
Pharmaceuticals
About
SEOUL PHARMA CO. ,LTD. is a pharmaceutical company based in Seoul, South Korea, focusing on the development and manufacturing of innovative medications for various health conditions, serving both chronic and acute needs. SEOUL PHARMA CO.
,LTD. was founded in 1985 and operates out of Seoul, South Korea. The company specializes in pharmaceutical products and has not undergone any major pivots in its business strategy. It is led by CEO Ebenezer Arko alongside Jack Man and Pablo Patiño.
The company has successfully raised a total of KRW 60 billion through PIPE funding, most recently in February 2020. No information indicates the presence of subsidiaries or parent companies. SEOUL PHARMA CO. ,LTD.
develops and manufactures a variety of pharmaceutical products, including prescription medications and over-the-counter treatments targeted at chronic and acute health conditions. The company emphasizes research and development to ensure compliance with regulatory standards and effectively meet the needs of healthcare providers and patients. Its customer base includes hospitals, healthcare professionals, and retail pharmacies, distributing products across key markets in North America, Europe, and Asia. In the most recent year, SEOUL PHARMA CO.
,LTD. reported a revenue of KRW 39,310,173. 10, with an EBITDA of KRW 2,948,283. 80.
The company generates revenue through partnerships with healthcare providers and direct sales to retailers and wholesalers, maintaining a structured B2B framework. SEOUL PHARMA CO. ,LTD. plans to utilize the KRW 60 billion raised in its most recent funding round to support the development of new pharmaceutical products and expand into additional markets.
The company is targeting growth in North America and Europe by the end of 2024, focusing on launching innovative products that address pressing healthcare needs. These strategic initiatives are aimed at enhancing the company’s market presence and overall growth in the pharmaceutical sector.
Current Investors
Q Capital Partners
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.seoulpharma.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
SEOUL PHARMA CO.,LTD. - timeline of key events
SEOUL PHARMA CO.,LTD. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 43,820,763,705 | 46,376,902,390 | 42,042,886,082 | 43,815,703,688 | 44,730,694,680 | 38,068,710,720 | 34,051,567,434 | 43,568,031,005 | 53,950,359,339 | 52,231,917,419 | 40,462,650,387 | 50,056,724,915 | - | - | - |
| % Revenue Growth (YoY) | - | 5.8% | (9.3%) | 4.2% | 2.1% | (14.9%) | (10.6%) | 27.9% | 23.8% | (3.2%) | (22.5%) | 23.7% | - | - | - |
| EBITDA (USD) | 3,281,096,275 | 8,067,919,494 | 3,814,535,817 | 2,196,867,323 | 4,460,543,784 | 856,249,624 | (3,428,554,669) | (2,655,684,334) | 6,160,662,503 | 8,554,761,196 | (3,185,319,211) | 4,351,811,291 | - | - | - |
| Operating Income (USD) | 1,886,216,275 | 6,101,943,684 | 1,334,972,940 | 677,345,323 | 675,242,784 | (2,126,608,376) | (5,965,143,669) | (4,909,178,334) | 3,662,971,503 | 6,111,420,196 | (5,713,492,211) | 1,738,725,291 | - | - | - |
| Operating Margin | 4.3% | 13.2% | 3.2% | 1.5% | 1.5% | (5.6%) | (17.5%) | (11.3%) | 6.8% | 11.7% | (14.1%) | 3.5% | - | - | - |
| % EBITDA Margin | 7.5% | 17.4% | 9.1% | 5.0% | 10.0% | 2.2% | (10.1%) | (6.1%) | 11.4% | 16.4% | (7.9%) | 8.7% | - | - | - |
| NET Income (USD) | 1,333,417,888 | 5,102,760,531 | 617,910,785 | (695,965,952) | (783,060,798) | (4,458,631,593) | (10,577,449,435) | (7,623,976,384) | (1,869,378,478) | (1,341,550,045) | (9,688,581,587) | 855,093,541 | - | - | - |
| % Net Margin | 3.0% | 11.0% | 1.5% | (1.6%) | (1.8%) | (11.7%) | (31.1%) | (17.5%) | (3.5%) | (2.6%) | (23.9%) | 1.7% | - | - | - |
SEOUL PHARMA CO.,LTD. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | SEOUL PHARMA CO.,LTD. | - |
Displaying 1 - 1 of 1
SEOUL PHARMA CO.,LTD. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.